Another Recommendation On Wall Street for Perrigo Company Plc (NYSE:PRGO). This time with a $167.00 Share Target Price


Why Has Morgan Stanley Given Perrigo Company Plc (NYSE:PRGO) a $167.00 Price Target

Morgan Stanley analyst initiated coverage on Perrigo Company Plc (NYSE:PRGO) with a $167.00 target price and Equal-weight rating. The target price could mean a potential upside of 14.28% from firm’s previous close.

From a total of 13 analysts covering Perrigo Company Plc (NYSE:PRGO) stock, 9 rate it a ”Buy”, 0 a “Sell”, and 6 a ”Hold”. This means that 60% of the ratings are positive. The highest target price is $237 while the lowest target price is $156. The mean of all analyst targets is $192.54 with a 34.86% above today’s ($146.26) stock price. Perrigo Company Plc was the topic of 8 analyst reports since October 23, 2015 according to the firm StockzIntelligence Inc. B. Riley & Co maintained shares on November 24 with “Buy” rating. UBS upgraded PRGO stock in a recent report from November 16 to “Buy” rating.

Approximately 518,193 shares of stock traded hands. Perrigo Company plc Ordinary Shares (NYSE:PRGO) has declined 19.33% since April 30, 2015 and is downtrending. It has underperformed by 19.04% the S&P500.

According to Zacks Investment Research, “Perrigo Company plc develops, manufactures and distributes healthcare products. The company operates primarily in four segments: Consumer Healthcare, Nutritionals, Rx Pharmaceutical and Active Pharmaceutical Ingredients. It also provides animal health products. The company operates primarily in the United States, the United Kingdom, Mexico, Israel, Australia, Canada, China and Latin America. Perrigo Company plc formerly known as Perrigo Company is headquartered in Ireland.” Get a free copy of the Zacks research report on Perrigo Company plc Ordinary Shares (PRGO).